Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

61. Hepatitis C: interventions for case-finding and linkage to care

Hepatitis C: interventions for case-finding and linkage to care Hepatitis C: interventions for case-finding and linkage to care - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Hepatitis C: interventions for case-finding and linkage to care An evidence review of what interventions are effective in increasing case-finding and linkage to care for hepatitis C-infected patients. Published 26 July 2019 From (...) need. It will help us if you say what assistive technology you use. Details This report summarises the evidence for interventions, to increase case-finding and linkage to care for hepatitis C-infected patients. It is intended to support commissioners and health and care providers, in making decisions on prioritisation of resources and the commissioning of services. It is part of the ongoing effort to eliminate hepatitis C virus ( Collection Explore the topic Is this page useful? Thank you for your

2019 Public Health England

62. Screening for hepatitis C

Screening for hepatitis C 1 Translation of the key statement of the final report S16-04 Screening auf Hepatitis C (Version 1.0; Status: 19 September 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-04 Screening for hepatitis C 1 Extract of final report S16-04 Version 1.0 (...) Screening for hepatitis C 19 September 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Screening for hepatitis C Commissioning agency: Federal Joint Committee Commission awarded on: 22 September 2016 Internal Commission No.: S16-04 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

63. The effects of message framing and healthcare provider recommendation on adult hepatitis B vaccination: A randomized controlled trial Full Text available with Trip Pro

The effects of message framing and healthcare provider recommendation on adult hepatitis B vaccination: A randomized controlled trial Many adults in the U.S. do not receive recommended vaccines, and the research literature remains inconclusive on the best communication strategies for increasing this behavior. This study examined the association of message framing (gained-framed vs. loss-framed vs. control), and healthcare provider (HCP) recommendation (offered vs. recommended) on uptake (...) of adult hepatitis B virus (HBV) vaccination in a high risk population using a 3 × 2 block design randomized controlled trial. Fear of shots, fear of vaccines, and perceived message framing were examined in secondary analyses. Of the 1747 participants, 47.7% (n = 833) received 0 doses of HBV vaccine, 27.8% (n = 485) received 1 dose, 10.4% received 2 doses, and 14.1% received all 3 recommended doses. There was not a significant interaction between message framing and HCP recommendation (p = .59). Mean

2019 EvidenceUpdates

64. Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-Center, Randomized, Noninferiority Trial Full Text available with Trip Pro

Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-Center, Randomized, Noninferiority Trial This study tested the hypothesis that the immunogenicity and safety of the simultaneous administration of enterovirus 71 (EV71) vaccine (dose 1) with recombinant hepatitis B vaccine (HepB) on day 1 and EV71 vaccine (dose 2) with group A meningococcal (...) ); or administration of HepB and MenA on days 1 and 30, respectively (the SE2 group).According to the per protocol set, antibody responses against EV71, hepatitis B virus (HBV), and group A meningococcal polysaccharide were similar regardless of administration schedule. With the non-inferiority margin setting at 10%, the seroconversion rates of the three pathogens in the SI group (100% [98.25, 100], 44.84% [38.20, 51.63] and 27.83% [21.91, 34.38]) were not inferior to those in SE1 or SE2 group (100% [98.31, 100

2019 EvidenceUpdates

65. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement

Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset (...)  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement Joseph Doyle, Michelle Raggatt, Monica Slavin, Sue‐Anne McLachlan, Simone I Strasser, Joseph J Sasadeusz, Jessica Howell, Krispin Hajkowicz, Harshal Nandurkar, Anna Johnston, Narin Bak and Alexander J Thompson Med J

2019 MJA Clinical Guidelines

66. Options for national testing and surveillance for hepatitis E virus in the EU/EEA

Options for national testing and surveillance for hepatitis E virus in the EU/EEA TECHNICAL REPORT Options for national testing and surveillance for hepatitis E virus in the EU/EEA Operational guidance www.ecdc.europa.euECDC TECHNICAL REPORT Options for national testing and surveillance for hepatitis E virus in the EU/EEA Operational guidance ii This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Cornelia Adlhoch and produced by Cornelia (...) on request. Representatives of the European Food Safety Authority (EFSA, Valentina Rizzi and Michaela Hempen) and the World Health Organization Regional Office for Europe (Antons Mozalevskis) were observers in this group and received documents for review. The work was supported by two service contracts No. ECD.7600 (HEV epidemiological support – P/2017/OCS/253) and No. ID 5132 (Hepatitis B, C, and E in the EU/EEA: monitoring and testing activities). The following staff were involved on the contractor’s

2019 European Centre for Disease Prevention and Control - Technical Guidance

67. Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. Full Text available with Trip Pro

Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update

2019 Annals of Internal Medicine

68. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. (Abstract)

Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Whether statin type influences hepatocellular carcinoma (HCC) incidence or mortality in chronic hepatitis B or C virus infection is unknown.To assess the relationship between lipophilic or hydrophilic statin use and HCC incidence and mortality in a nationwide population with viral hepatitis.Prospective propensity score (PS)-matched (...) , -7.6 to -4.2 percentage points]; aHR, 0.41 [CI, 0.32 to 0.61]), and 10-year mortality was significantly lower among both lipophilic (15.2% vs. 7.3%; RD, -7.9 percentage points [CI, -9.6 to -6.2 percentage points]) and hydrophilic (16.0% vs. 11.5%; RD, -4.5 percentage points [CI, -6.0 to -3.0 percentage points]) statin users.Lack of lipid, fibrosis, or HCC surveillance data.In a nationwide viral hepatitis cohort, lipophilic statins were associated with significantly reduced HCC incidence

2019 Annals of Internal Medicine

69. Acupuncture for chronic hepatitis B. Full Text available with Trip Pro

Acupuncture for chronic hepatitis B. Chronic hepatitis B is a liver disease associated with high morbidity and mortality. Chronic hepatitis B requires long-term management aiming to reduce the risks of hepatocellular inflammatory necrosis, liver fibrosis, decompensated liver cirrhosis, liver failure, and liver cancer, as well as to improve health-related quality of life. Acupuncture is being used to decrease discomfort and improve immune function in people with chronic hepatitis B. However (...) , the benefits and harms of acupuncture still need to be established in a rigorous way.To assess the benefits and harms of acupuncture versus no intervention or sham acupuncture in people with chronic hepatitis B.We undertook electronic searches of the Cochrane Hepato-Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, LILACS, Science Citation Index Expanded, Conference Proceedings Citation Index - Science, China National Knowledge Infrastructure (CNKI), Chongqing VIP (CQVIP), Wanfang Data

2019 Cochrane

70. Daratumumab (Darzalex): risk of reactivation of hepatitis B virus

Daratumumab (Darzalex): risk of reactivation of hepatitis B virus Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus Establish hepatitis B virus status before initiating daratumumab and in patients with unknown hepatitis B virus serology who are already being treated with daratumumab (...) . Published 19 August 2019 From: Therapeutic area: , , , , Contents Advice for healthcare professionals: hepatitis B virus reactivation has been reported in patients treated with daratumumab, including several fatal cases worldwide screen all patients for hepatitis B virus before initiation of daratumumab; patients with unknown serology who are already on treatment should also be screened monitor patients with positive serology for clinical and laboratory signs of hepatitis B reactivation during treatment

2019 MHRA Drug Safety Update

71. What is the pathophysiology behind hepatic osteopenia/osteoporosis and who should be screened for it?

What is the pathophysiology behind hepatic osteopenia/osteoporosis and who should be screened for it? Chiefs’ Inquiry Corner August 5th, 2019 – Clinical Correlations Search Chiefs’ Inquiry Corner August 5th, 2019 August 5, 2019 2 min read Patients with chronic liver disease are nearly three times more likely to develop osteoporosis than matched controls. In contrast to patients with post-menopausal osteoporosis, in whom increased osteoclast activity depletes bone density, the mechanism (...) in patients with liver disease is thought to be driven by decreased osteoblast activity. Patients with liver disease see decreases in osteoblastogenesis stimulating factors such as IGF-1 and vitamin K and increases in serum bilirubin, which directly inhibits osteoblastogenesis. It is recommended to screen the following female and male patients for hepatic osteopenia: All patients with cirrhosis All patients with chronic cholestasis (bilirubin >3mg/dL for 6 months) All potential liver transplant candidates

2019 Clinical Correlations

72. Screening for Hepatitis B Virus Infection in Pregnant Women: US Preventive Services Task Force Reaffirmation Recommendation Statement. Full Text available with Trip Pro

Screening for Hepatitis B Virus Infection in Pregnant Women: US Preventive Services Task Force Reaffirmation Recommendation Statement. Screening for hepatitis B virus (HBV) infection during pregnancy identifies women whose infants are at risk of perinatal transmission. Data from a nationally representative sample showed a prevalence of maternal HBV infection of 85.8 cases per 100 000 deliveries from 1998 to 2011 (0.09% of live-born singleton deliveries in the United States). Although (...) commissioned a reaffirmation evidence update to identify substantial new evidence sufficient enough to change the prior recommendation. The USPSTF targeted its evidence review on the effectiveness and potential harms of screening and the effectiveness and harms of case management to prevent perinatal transmission.The USPSTF previously found adequate evidence that serologic testing for hepatitis B surface antigen accurately identifies HBV infection. Interventions are effective for preventing perinatal

2019 JAMA

73. Hepatitis B vaccine for renal patients: patient group direction template

Hepatitis B vaccine for renal patients: patient group direction template application/vnd.openxmlformats-officedocument.wordprocessingml.document

2019 Public Health England

74. An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitut (Abstract)

An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitut A 12-week grazoprevir/elbasvir regimen is highly effective against hepatitis C virus genotype 1 (HCV-1) infection. The efficacy of an 8-week regimen for treatment-naive HCV-1-infected patients with mild fibrosis has not been

2019 EvidenceUpdates

75. Hepatitis E: symptoms, transmission, prevention, treatment

Hepatitis E: symptoms, transmission, prevention, treatment Hepatitis E: symptoms, transmission, treatment and prevention - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Hepatitis E: symptoms, transmission, treatment and prevention Updated 8 March 2019 Contents © Crown copyright 2019 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view (...) this licence, visit or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: . Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at https://www.gov.uk/government/publications/hepatitis-e-symptoms-transmission-prevention-treatment/hepatitis-e-symptoms-transmission-treatment-and-prevention Background Hepatitis E is an illness of the liver caused

2019 Public Health England

76. New Direct-acting Antiviral for Hepatitis C (Epclusa?

New Direct-acting Antiviral for Hepatitis C (Epclusa? MED CHECK April 2019/ Vol.5 No.13 · Page C N o 13 M ED HECK A p r i l 2 0 1 9 Accelerated Approval, Ignoring Harm, is a Crime New Direct-acting Antiviral for Hepatitis C (Epclusa ) Hemorrhage caused by an Anti-influenza Agent, Baloxavir Editorial Accelerated Approval, Ignoring Harm, is a Crime New Products New Direct-acting Antiviral for Hepatitis C (Epclusa ) Advance in hepatitis C with prior treatment failure or decompensated cirrhosis (...) for whom an anti-influenza drug should be effective. However, if you have severe flu symptoms, you may lose appetite and cannot eat. Then, you have to avoid using Xofluza due to the high risk of bleeding. After all, just like Tamiflu, Xofluza has no place in use for influenza infection. Accelerated approval, ignoring harm, is a crime.MED CHECK April 2019/ Vol.5 No.13 · Page New Direct-acting Antiviral for Hepatitis C ( Epclusa ) Advance in hepatitis C with prior treatment failure or decompensated

2019 Med Check - The Informed Prescriber

77. Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multicenter Study Full Text available with Trip Pro

Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multicenter Study Frailty is associated with mortality in patients with cirrhosis. We measured frailty using 3 simple tests and calculated Liver Frailty Index (LFI) scores for patients at multiple ambulatory centers. We investigated associations between LFI scores, ascites, and hepatic encephalopathy (HE) and mortality.Adults without hepatocellular carcinoma who were on the liver transplantation

2019 EvidenceUpdates

78. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. Full Text available with Trip Pro

Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. Many people who inject drugs (PWID) are denied treatment for hepatitis C virus (HCV) infection, even if they are receiving opioid agonist therapy (OAT). Research suggests that HCV in PWID may be treated effectively, but optimal models of care for promoting adherence and sustained virologic response (SVR) have not been evaluated in the direct-acting antiviral (DAA

2019 Annals of Internal Medicine Controlled trial quality: predicted high

79. Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B. Full Text available with Trip Pro

Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B. Hepatitis B virus (HBV) infection, a liver disease caused by hepatitis B virus, may lead to serious complications such as cirrhosis and hepatocellular carcinoma. People with HBV infection may have co-infections including HIV and other hepatitis viruses (hepatitis C or D), and co-infection may increase the risk of all-cause mortality. Chronic HBV infection increases morbidity and psychological stress (...) and is an economic burden on people with chronic hepatitis B and their families. Radix Sophorae flavescentis, an herbal medicine, is administered most often in combination with other drugs or herbs. It is believed that it decreases discomfort and prevents replication of the virus in people with chronic hepatitis B. However, the benefits and harms of Radix Sophorae flavescentis for patient-centred outcomes are not known, and its wide usage has never been established with rigorous review methodology.To assess

2019 Cochrane

80. Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients. Full Text available with Trip Pro

Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients. Currently, there is no specific immunosuppressive protocol for hepatitis C (HCV)-positive renal transplants recipients. Thus, the aim of this study was to evaluate the conversion effect to everolimus (EVR) on HCV in adult kidney recipients.This is an exploratory single-center, prospective, randomized, open label controlled trial with renal allograft recipients with HCV

2019 Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia Controlled trial quality: uncertain